Peritoneal metastasis in gastric cancer: Mechanisms and management strategies

Abstract

Author(s): Pratibha Pandey*, Malathi H and Dhwani Bartwal

Background: Surgical trauma or full-thickness invasion of gastrointestinal cancer through the gut wall might cause peritoneal surface malignancy.

Objective: This research examined the mechanisms and treatment options for Peritoneal Metastases (PM) in gastric cancer.

Material and Methods: Using data on cancer and demographics from the National Cancer Centre (NCC) in India for 2016, PM prevalence in 2020 was projected. Gastric Cancer (GC), which ranks third in terms of frequency, has a 25% 5-year survival rate. This is a result of PM. Palliative Systemic Chemotherapy (SCT) should be given to PM-GC for six months. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery (CRS) are popular peritoneal carcinoma treatments in 2016. Survival of GC with PM is improved by CRS and HIPEC. In patients with locally advanced GC who do not have macroscopic PM, HIPEC, and other intraperitoneal therapies can prevent peritoneal recurrences. Laparoscopic HIPEC and NIPS minimize peritoneal disease and promote cytoreduction.

Results: In India gastric cancer PM rates: 523,937 instances, PM 371.0 per million. India needs 1194 specialized PM treatment centres to treat 365 high-quality patients annually. India has 1580 top-tier tertiary hospitals. Since this is the case, India should have at least 2 PM treatment centres open for every 3 first-rate tertiary hospitals.

Conclusion: A large number of people with PM in India demand further investment in the country's limited network of specialized PM treatment institutions. Finally, Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) or laparoscopic HIPEC can manage malignant ascites symptoms in individuals with the high-volume peritoneal illness.

Share this article